Day One Biopharmaceuticals, Inc.
DAWN$972M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBRISBANE184 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Feb 15, 2026
7dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
2 upcoming, 1 past
⭐Phase 3Next
Chemotherapeutic Agent Phase 3 Results Expected
February 2026~Chemotherapeutic Agent400
Primary completion for Chemotherapeutic Agent trial (NCT05566795) in Low-grade Glioma
Source⭐Phase 3
Tovorafenib Phase 3 Results Expected
February 2026~Tovorafenib400
Primary completion for Tovorafenib trial (NCT05566795) in Low-grade Glioma
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Chemotherapeutic Agent | Phase 3 | Low-grade Glioma | - |
Tovorafenib | Phase 3 | Low-grade Glioma | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
DAWN News